| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about the latest innovations in packaging and aseptic filling solutions that meet the complex demands of emerging therapies. Discover how to ensure product integrity, safety and efficiency. Register now. 
|
|
Today’s Big NewsJan 15, 2025 |
|
Connecting the Innovation Districts in Cincinnati, Columbus and Cleveland, the Ohio Discovery Corridor drives opportunity, innovation, and collaboration unlike anywhere else in the Midwest. Explore the corridor. 
|
|
| By Gabrielle Masson Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge about genetic factors driving disease. And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways to build past the GLP-1 space. |
|
|
|
By James Waldron A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension drug, Keros Therapeutics has now pulled the plug on the study entirely. |
By James Waldron OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. |
By Nick Paul Taylor Neumora Therapeutics’ phase 3 fail was worse than analysts feared. The biotech provided a closer look at the data Tuesday, shutting down one source of hope that analysts had clung to after the initial blow. |
|
With so many options, finding the ideal test system can be a challenge, so BioIVT compiled a guide outlining the differences with recommendations for different studies, tips on their use and more... Download Now >> 
|
|
By Ben Adams,Gabrielle Masson,Darren Incorvaia,James Waldron Welcome to day 3 of the J.P. Morgan Healthcare Conference in San Francisco. |
By Darren Incorvaia Daiichi Sankyo is turning to the German hamlet of Heidelberg for help developing antibodies. The Japanese pharma giant is teaming up with independent research institute BioMed X to form a new research group to work on targeting solid tumors with multispecific biologics, including antibodies. |
By Darren Incorvaia N-Power Medicine, a tech firm with a clinical trial platform for capturing real-world patient data, has acquired precision medicine firm Syapse Holdings. The buy links N-Power with Syapse’s network of 1,000 community oncologists and empowers it with Syapse’s data, technology and team. |
By Paige Minemyer First Lady Jill Biden's time in the White House will come to a close less than a week from now, but she said Tuesday that's not going to bring her work around women's health to a halt. |
By Angus Liu,Zoey Becker,Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more companies are set to take the stage on Wednesday. |
By Fraiser Kansteiner,Kevin Dunleavy Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over well with investors. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
